Geode Capital Management
TXG icon

Geode Capital Management’s 10x Genomics TXG Stock Holding History

Geode Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118M Buy
3,082,790
+178,562
+6% +$4.68M 0.01% 1083
2026
Q1 		$61.7M Buy
2,904,228
+114,444
+4% +$2.29M ﹤0.01% 1384
2025
Q4 		$45.5M Buy
2,789,784
+78,541
+3% +$1.19M ﹤0.01% 1543
2025
Q3 		$31.7M Buy
2,711,243
+60,424
+2% +$788K ﹤0.01% 1759
2025
Q2 		$30.7M Buy
2,650,819
+773,203
+41% +$7.05M ﹤0.01% 1711
2025
Q1 		$16.4M Buy
1,877,616
+62,793
+3% +$792K ﹤0.01% 1999
2024
Q4 		$26.1M Sell
1,814,823
-887
-0% -$14K ﹤0.01% 1819
2024
Q3 		$41M Buy
1,815,710
+42,777
+2% +$884K ﹤0.01% 1551
2024
Q2 		$34.5M Buy
1,772,933
+129,780
+8% +$3.4M ﹤0.01% 1611
2024
Q1 		$61.7M Buy
1,643,153
+55,338
+3% +$2.43M 0.01% 1214
2023
Q4 		$88.9M Buy
1,587,815
+68,771
+5% +$2.99M 0.01% 939
2023
Q3 		$62.7M Buy
1,519,044
+84,243
+6% +$4.38M 0.01% 1073
2023
Q2 		$80.1M Buy
1,434,801
+68,905
+5% +$3.73M 0.01% 933
2023
Q1 		$76.2M Buy
1,365,896
+44,662
+3% +$2.09M 0.01% 907
2022
Q4 		$48.1M Buy
1,321,234
+63,324
+5% +$2.07M 0.01% 1171
2022
Q3 		$35.8M Buy
1,257,910
+38,393
+3% +$1.46M 0.01% 1329
2022
Q2 		$55.2M Buy
1,219,517
+31,078
+3% +$1.61M 0.01% 1041
2022
Q1 		$90.3M Buy
1,188,439
+28,984
+2% +$2.54M 0.01% 833
2021
Q4 		$173M Buy
1,159,455
+30,714
+3% +$4.7M 0.02% 586
2021
Q3 		$164M Buy
1,128,741
+119,254
+12% +$20.5M 0.02% 583
2021
Q2 		$197M Buy
1,009,487
+107,662
+12% +$19.5M 0.03% 538
2021
Q1 		$163M Buy
901,825
+113,719
+14% +$19.6M 0.02% 568
2020
Q4 		$111M Buy
788,106
+102,357
+15% +$14.9M 0.02% 644
2020
Q3 		$85.5M Buy
685,749
+381,564
+125% +$40.1M 0.02% 663
2020
Q2 		$27.2M Buy
304,185
+198,559
+188% +$15.5M 0.01% 1277
2020
Q1 		$6.58M Buy
105,626
+15,754
+18% +$1.23M ﹤0.01% 1987
2019
Q4 		$6.85M Buy
+89,872
New +$5.4M ﹤0.01% 2267

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's TXG Position: Q2 2026 in Review

Geode Capital Management increased its 10x Genomics (TXG) stake by 6.1% in Q2 2026, buying an estimated $4.68M and bringing the position to 3,082,790 shares worth $118M. The position accounts for 0.01% of the portfolio, ranked #1083.

Geode Capital Management first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $197M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Geode Capital Management held 3,082,790 shares of 10x Genomics worth $118M as of Q2 2026.
  • Geode Capital Management bought 178,562 10x Genomics shares in Q2 2026, an estimated $4.68M.
  • 10x Genomics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1083 holding.
  • Geode Capital Management first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • Geode Capital Management's 10x Genomics position peaked at $197M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.